Regression of Grade III Astrocytoma During the Treatment of CML with Imatinib Mesylate

Abstract

Astrocytomas are central nervous system neoplasms, which are derived predominately from astrocytes. On the basis of the histopathologic characteristics astrocytomas are graded from I to IV. The cells that demonstrate the greatest degree of anaplasia are used to determine the histologic grade of the tumor. The mean age of survival are approximately 10 years from the time of diagnosis for pilocystic astrocytomas (World Health Organization grade I), more than 5 years for patients with low-grade diffuse astrocytomas (WHO grade II), 2 to 5 years for those with anaplastic astrocytomas (WHO grade III), and less than 1 year for patients with glioblastoma (WHO grade IV). The treatment is a combination of surgery, radiation, and chemotherapy depending of the grade of astrocytoma. We present a case of 31-year-old man with grade III astrocytoma with subsequent chronic myelogenous leukemia treated with imatinib mesylate as part of his chronic myelogenous leukemia treatment failing to show recurrence of the astrocytoma 10 years after standard treatment for astrocytoma.

Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor

“…A report by Geng et al showing that imatinib treatment of mouse GBM brain tumor models resulted in reduced phospho-PDGFR levels in GBM cells provides preclinical evidence in support of this hypothesis (30). In addition, a number of clinical reports demonstrating the efficacy of imatinib in brain tumor patients similarly support this argument (31, 32), indicating that further preclinical testing of imatinib treatment of medulloblastoma is warranted.…”

An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy

“…Despite the progress of glioma treatment in recent years, the median survival of patients remains less than two years (28)(29)(30). Therefore, great need exists for designing new therapeutic techniques and modifying old ones.…”

Amphiphilic Poly(2-oxazoline)s with Glycine-Containing Hydrophobic Blocks Tailored for Panobinostat- and Imatinib-Loaded Micelles

“…Panobinostat and imatinib represent two potential anticancer drug candidates that seem promising for the treatment of brain cancer, i . e ., glioblastoma and medulloblastoma. − The histone deacetylase inhibitor panobinostat is used in the treatment of multiple myeloma. − Imatinib, a potent tyrosine kinase inhibitor (TKI), is currently used to treat chronic myelogenous leukemia, , gastrointestinal stromal tumors, − and other malignant tumors …”

“…1−4 The histone deacetylase inhibitor panobinostat is used in the treatment of multiple myeloma. 5−8 Imatinib, a potent tyrosine kinase inhibitor (TKI), is currently used to treat chronic myelogenous leukemia, 9,10 gastrointestinal stromal tumors, 11−13 and other malignant tumors. 14 However, particularly, panobinostat suffers from a low bioavailability due to its low solubility in water.…”